Evidence map›Paper›PMID 38884356›Full record

ArticleDevelopment (Cambridge, England)2024

BET activity plays an essential role in control of stem cell attributes in Xenopus.

Paul B Huber, Anjali Rao, Carole LaBonne

Abstract read
In one paragraph

Article in Development (Cambridge, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paul B HuberDepartment of Molecular Biosciences, Northwestern University, Evanston, IL 60208, USA.
Anjali RaoDepartment of Molecular Biosciences, Northwestern University, Evanston, IL 60208, USA.
Carole LaBonneDepartment of Molecular Biosciences, Northwestern University, Evanston, IL 60208, USA.ORCID 0000-0001-6001-7179

Funding

Neural Crest Ontogeny and the Control of Stem Cell AttributesR01GM116538 · NIGMS · NORTHWESTERN UNIVERSITY · PI LABONNE, CAROLE · 2015 to 2018
$1.2M
National Science Foundation 1764421NIGMS NIH HHS R01 GM116538NIGMS NIH HHS R01GM116538NIH HHS R01GM116538NSF 1764421Simons Foundation SFARI 597491-RWC
6 · The paper itself

Abstract

Neural crest cells are a stem cell population unique to vertebrate embryos that retains broad multi-germ layer developmental potential through neurulation. Much remains to be learned about the genetic and epigenetic mechanisms that control the potency of neural crest cells. Here, we examine the role that epigenetic readers of the BET (bromodomain and extra terminal) family play in controlling the potential of pluripotent blastula and neural crest cells. We find that inhibiting BET activity leads to loss of pluripotency at blastula stages and a loss of neural crest at neurula stages. We compare the effects of HDAC (an eraser of acetylation marks) and BET (a reader of acetylation) inhibition and find that they lead to similar cellular outcomes through distinct effects on the transcriptome. Interestingly, loss of BET activity in cells undergoing lineage restriction is coupled to increased expression of genes linked to pluripotency and prolongs the competence of initially pluripotent cells to transit to a neural progenitor state. Together these findings advance our understanding of the epigenetic control of pluripotency and the formation of the vertebrate neural crest.

Indexed as

Neural CrestAnimalsBlastulaCell DifferentiationEpigenesis, GeneticGene Expression Regulation, DevelopmentalPluripotent Stem CellsTranscriptomeXenopus laevisXenopus ProteinsXenopus ProteinsBrd4BromodomainHistone AcetylationNeural crestPluripotencyStem cellXenopus

Identifiers

PMID38884356
PMCPMC11266789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.